{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Progressive Disease requires 1 or more of the following:\n\nIncrease of ≥ 25% from baseline in:\n\nSerum M-component and/or (increase ≥ 0.5 g/dL).\n\nUrine M-component and/or (increase ≥ 200 mg/24 h).\n\nIn patients without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels increase must be \\> l0 mg/dL.\n\nBone marrow plasma cell percentage ≥ 10%.\n\nDefinite development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas.\n\nDevelopment of hypercalcemia.","groups":[{"description":"Patients received ruxolitinib 25 mg orally twice daily (bid) in each treatment cycle of 28 days. For those patients who had disease progression at any time or stable disease for 3 cycles and did not meet a withdrawal criterion or withdrew consent then 40 mg of dexamethasone was added to ruxolitinib on Days 1 to 4, 9 to 12, and 17 to 20 for four 28-day cycles. After the 4th cycle, 40 mg of dexamethasone was administered only on Days 1 to 4 of each subsequent cycle. Patients could continue to receive monotherapy or combination therapy indefinitely as long as no withdrawal criterion was met, did not have progressive disease and were receiving some clinical benefit.","id":"OG000","title":"Ruxolitinib Then Ruxolitinib + Dexamethasone"}],"populationDescription":"Intent-to-treat population. This outcome measure was not analyzed as no patients achieved a response.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycles 2, 3, and 4 and then every 3 months thereafter (up to 25 months).","title":"Time to Disease Progression According to the International Uniform Response Criteria for Multiple Myeloma","type":"SECONDARY"}